Characterization of Neurotoxicity After CAR-T in LBCL
Neurotoxicity is a common AE associated with CAR-T administration, but there are limited data characterizing it among patients with LBCL who received axi-cel.
CAR-T Therapy
Can Culturing CAR T Cells With Ibrutinib Improve Their Efficacy in CLL?
Sustained remission of CLL is associated with enrichment of a less-differentiated, early-memory phenotype of T cells in the apheresis product used to make CAR-T therapies.
G-CSF Appears Safe in CAR-T–Treated Patients With Refractory/Relapsed B-Cell Lymphoma
The treatment reduced hospital stay but not neutropenia duration or infection rate.
Development of a Tool to Predict Neurotoxicity Associated With CAR-T Therapy
The occurrence, severity, and need for treatment of cytokine release syndrome were key parameters in the assessment of CAR-T–related neurotoxicity risk.
New NCCN Patient Guidelines Feature Immunotherapy, CAR-T Side Effects
The NCCN recently released 2 sets of Guidelines for Patients that explain the side effects of different types of immunotherapies, such as CAR T-cell therapies.
Early-Memory T-Cell Population May Predict CAR-T Efficacy in Several Hematological Malignancies
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.
Close Monitoring, Full-Time Caregiver Recommended for 30 Days After CAR-T Therapy
Readmissions for CRS, neurotoxicity, infection, and other adverse events are common after immunotherapy with axicabtagene ciloleucel.
Hemophagocytic Lymphohistiocytosis and CAR-T Cell Therapy
Progression-free and overall survival were worse among patients with HLH receiving CAR-T cell therapy by 10-month follow-up.
Patient Relapse Time After Auto-HCT in Chemosensitive DLBCL Does Not Appear to Influence PFS
The data reinforce the need for direct comparison of CAR-T and autologous transplantation.
- Loading...
Loading...
Next post in ASCO 2020
Loading... 
Loading...